Big Pharma Isn’t Just Buying From China Anymore — It’s Building With It

Bristol Myers Squibb’s expanding partnership strategy signals how China is evolving from a biotech sourcing market into a core pillar of global pharmaceutical R&D

The agreement includes four immunology assets for co-development alongside five new innovative assets to be jointly discovered by both companies, marking one of the clearest examples yet of Western pharma integrating Chinese biotech into long-term R&D strategy.

The deal also reinforces how China is evolving from a manufacturing and commercial market into a core source of pharmaceutical innovation, with BMS directing nearly 50% of its global upfront deal cash since 2024 into the region.

China Is Becoming More Than a Licensing Market

For years, Western pharmaceutical companies primarily viewed China as a growth market or manufacturing base. That dynamic is now changing rapidly.

Rather than simply acquiring rights to late-stage assets, global pharma companies are increasingly embedding themselves deeper into Chinese biotech ecosystems through strategic partnerships, co-development structures and shared discovery platforms.

BMS’s latest agreement with Hengrui reflects this evolution. Unlike more traditional licensing arrangements, the partnership involves collaborative R&D and long-term pipeline generation rather than isolated asset acquisition.

The company has already demonstrated this growing focus through its $1.5 billion deal involving BioNTech and Biotheus centred around a PD-(L)1/VEGF bispecific antibody.

Why This Matters for the Pharmaceutical Industry

The deal highlights several wider trends reshaping global pharma:

• Chinese biotech companies becoming central innovation partners rather than regional operators

• Western pharma increasing reliance on external R&D ecosystems

• Co-development models replacing purely transactional licensing agreements

• China emerging as a major source of next-generation immunology and oncology assets
  

Major pharmaceutical companies including AstraZeneca, Roche, Merck & Co. and AbbVie have all expanded their China deal activity in recent years.

However, BMS’s concentration of capital allocation toward the region suggests a particularly aggressive strategic positioning.

What This Means Going Forward

The BMS–Hengrui partnership reflects how the global balance of pharmaceutical innovation may be shifting eastward.

As Chinese biotech capabilities continue to mature, partnerships are becoming less about opportunistic access to individual assets and more about integrating China directly into long-term pipeline strategy.

This raises broader strategic questions for the industry around supply chains, intellectual property, geopolitical exposure and future R&D dependence.

At the same time, it reinforces the growing reality that many of the next decade’s most important pharmaceutical breakthroughs may increasingly emerge from collaborative global innovation networks centred around China.

Summary

Bristol Myers Squibb’s expanded partnership with Hengrui Pharma signals a deeper shift in how global pharma companies engage with China’s biotech sector.

As co-development and shared discovery models accelerate, China is increasingly positioning itself not just as a market for pharmaceuticals, but as one of the industry’s most important engines of innovation.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com